Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Der Nervenarzt
Erschienen in: Der Nervenarzt 8/2004

01.08.2004 | Aktuelles

Einsatz von i. v. Immunglobulinen in der Neurologie

Evidenzbasierter Konsens

verfasst von: Priv.-Doz. Dr. M. Stangel, R. Gold

Erschienen in: Der Nervenarzt | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zu verschiedenen neurologischen Autoimmunerkrankungen gibt es für hoch dosierte i. v. Immunglobuline (IVIg) inzwischen überzeugende Ergebnisse aus den nach modernen Standards durchgeführten, plazebokontrollierten Therapiestudien. Dennoch sind sie bei neurologischen Erkrankungen lediglich für das Guillain-Barré-Syndrom zugelassen. Es muss daher ein gezielter Einsatz von IVIg gefordert werden, da eine wirksame Therapie dem Patienten nicht vorenthalten werden darf, insbesondere wenn IVIg nicht durch gleichwertige Alternativen ersetzt werden können. Die hier vorgelegte Arbeit repräsentiert und gewichtet die verfügbaren Studienergebnisse zum Einsatz von IVIg. Auf der Basis dieser Evidenz wurden Empfehlungen zur Therapie mit IVIg erarbeitet, die auf einem breiten Konsens einer international ausgewiesenen, deutschsprachigen Neurologengruppe basieren. Dadurch soll zukünftig ein gezielter Einsatz von IVIg bei neurologischen Autoimmunerkrankungen gewährleistet werden.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Achiron A, Barak Y, Miron S et al. (2000) Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 23:551–555CrossRefPubMed
2.
Achiron A, Gabbay U, Gilad R et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398–402PubMed
3.
Al-Mayouf SM, Laxer RM, Schneider R et al. (2000) IVIg therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27:2498–2503PubMed
4.
Alessi G, De Reuck J, De Bleecker J et al. (2000) Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg 102:173–175CrossRefPubMed
5.
Apak RA, Anlar B, Saatci I (1999) A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 21:279–282CrossRefPubMed
6.
Arsura EL, Bick A, Brunner NG et al. (1988) Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 295:438–443PubMed
7.
Azulay J-P, Blin O, Pouget J et al. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44:429–432PubMed
8.
Bain PG, Motomura M, Newsom-Davis J et al. (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47:678–683PubMed
9.
Bamberg C, Janzen RWC, Szabados M (1996) Zur Langzeitbehandlung mit 7S-Immunglobulinen bei Myasthenia gravis. Nervenarzt 67:327–332PubMed
10.
Bien CG, Elger CE, Wiendl H (2002) Advances in pathogenic concepts and therapeutic agents in Rasmussen’s encephalitis. Expert Opin Invest Drugs 11:981–989
11.
Bien CG, Kuczaty S, Sassen R et al. (2003) Treatment of Rasmussen’s encephalitis with tacrolimus. Neuropediatrics 6:A49–A50
12.
Boman S, Ballen JL, Seggev JS (1995) Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 238:375–377PubMed
13.
Breems DA, Haas PW de, Visscher F et al. (1993) IVIg as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 137:2509–2510PubMed
14.
Bril V, Ilse WK, Pearce R et al. (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46:100–103PubMed
15.
Canhao H, Fonseca JE, Rosa A (2000) Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren’s syndrome. J Rheumatol 27:1102–1103PubMed
16.
Cappa M, Bertinti E, Balzo P del et al. (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry (Suppl) 57:69–70PubMed
17.
Cherin P, Herson S (1994) Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry (Suppl) 57:50–54PubMed
18.
Cherin P, Pelletier S, Teixeira A et al. (2002) Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467–474CrossRefPubMed
19.
Comi G, Roveri L, Swan A et al. (2002) A randomised controlle trial of intravonous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370–1377CrossRefPubMed
20.
Confavreux C, Hutchinson M, Hours MM et al. (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285–291CrossRefPubMed
21.
Cook D, Dalakas M, Galdi A et al. (1990) High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 40:212–214PubMed
22.
Dalakas M, Fujii M, Li M et al. (2001) High-dose intravenous immune globulin for stiff person syndrome. N Engl J Med 345:1870–1876CrossRefPubMed
23.
Dalakas M, Koffman B, Fujii M et al. (2001) A controlled study of IVIg combined with prednisone in the treatment of IBM. Neurology 56:323–327PubMed
24.
25.
Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000CrossRefPubMed
26.
Dalakas MC, Quarles RH, Farrer RG et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792–795PubMed
27.
Dalakas MC, Sonies B, Dambrosia J et al. (1997) Treatment of inclusion-body myositis wiith IVIg: a double-blind, placebo-controlled study. Neurology 48:712–716PubMed
28.
Dalakas MC, Stein DP, Otero C et al. (1994) Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 51:861–864PubMed
29.
Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554CrossRefPubMed
30.
Dupond JL, Gil H, de Wazieres B (1999) Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren’s syndrome. Am J Med 106:125–125
31.
Durez P, Tourne L, Feremans W et al. (1998) Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren’s syndrome. J Rheumatol 25:1032–1033PubMed
32.
Duse M, Notarangelo LD, Tiberti S et al. (1996) Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol (Suppl 1) 104:71–76
33.
Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845PubMed
34.
Fazekas F, Deisenhammer F, Strasser-Fuchs S et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589–593CrossRefPubMed
35.
Federico P, Zochodne DW, Hahn AF et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256–1262PubMed
36.
Finkel TH, Torok TJ, Ferguson PJ et al. (1994) Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255-1258CrossRefPubMed
37.
Finsterer J, Engelmayer E, Trnka E et al. (2000) Immunoglobulins are effective in pontine myelinolysis. Clin Neuropharmacol 23:110–113CrossRefPubMed
38.
Gajdos P, Chevret S, Clair B et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41:789–796PubMed
39.
Gorson KC, Ropper AH, Weinberg DH et al. (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772CrossRefPubMed
40.
Gottfried I, Seeber A, Anegg B et al. (2000) High dose IVIg in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29–35PubMed
41.
Gultekin SH, Rosenfeld MR, Voltz R et al. (2000) Paraneoplastic limbic encephalitis: tumor association, neurological symptoms, and immunological findings in 50 patients. Brain 123:1481–1494CrossRefPubMed
42.
Haas J (2000) High dose IVIg in the post partum period for prevention of exacerbations in MS. Mult Scler (Suppl 2) 6:S18–S20
43.
Hadden RD, Cornblath DR, Hughes RA et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780–788PubMed
44.
Hahn AF, Bolton CF, Zochodne D et al. (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119:1067–1077PubMed
45.
Hahn JS, Siegler DJ, Enzmann D (1996) Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 46:1173–1174PubMed
46.
Hart YM, Cortez M, Andermann F et al. (1994) Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44:1030–1036PubMed
47.
Hebbar M, Hebbar-Savean K, Hachulla E et al. (1995) Participation of cryoglobulinaemia in the severe peripheral neuropathies of primary Sjogren’s syndrome. Ann Interne Med 146:235–238
48.
Hermosilla E, Lagueny A, Vital C et al. (1996) Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Peripher Nerv Syst 1:139–148PubMed
49.
Hilkevich O, Drory VE, Chapman J et al. (2001) The use of immunoglobulin as maintainance therapy in myasthenia gravis. Clin Neuropharmacol 24:173–176CrossRefPubMed
50.
Höllinger P, Sturzenegger M (2000) Chronic progressive primary lumbosacral plexus neuritis: MRI findings and response to immunoglobulin therapy. J Neurol 247:143–145PubMed
51.
Hughes RAC, Bensa S, Willison H et al. (2001) Randomized controlled trial of intravenous immunoglobulin (IVIg) versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201CrossRefPubMed
52.
Jann S, Bramerio MA, Beretta S et al. (2003) Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 61:1607–1610PubMed
53.
Jayne DR, Chapel H, Adu D et al. (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 93:433–439CrossRef
54.
Jayne DR, Lockwood CM (1993) Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336:469–472PubMed
55.
Jayne DR, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150–1153CrossRefPubMed
56.
Jayne DR, Rasmussen N (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community systemic vasculitis clinical trials study group. Mayo Clin Proc 72:737–747PubMed
57.
Korinthenberg R (1998) Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Eur J Paediatr Neurol 2:57–59PubMed
58.
Krauss GL, Campbell ML, Roche KW et al. (1996) Chronic steroid-responsive encephalitis without autoantibodies to glutamate receptor GluR3. Neurology 46:247–249PubMed
59.
Leach JP, Chadwick DW, Miles JB et al. (1999) Improvement in adult-onset Rasmussen’s encephalitis with long- term immunomodulatory therapy. Neurology 52:738–742PubMed
60.
Leger JM, Ben Younes-Chennoufi A, Chassande B et al. (1994) Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry (Suppl) 57:46–49PubMed
61.
Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double blind, placebo-controlled study. Brain 124:145–153CrossRefPubMed
62.
Levy Y, Sherer Y, Ahmed A et al. (1999) A study of 20 SLE patients with intravenous immunoglobulin—clinical and serologic response. Lupus 8:705–712CrossRefPubMed
63.
Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565–572CrossRefPubMed
64.
Liguori R, Vincent A, Clover L et al. (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124:2417–2426CrossRefPubMed
65.
Mariette X, Chastang C, Clavelou P et al. (1997) A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 63:28–34PubMed
66.
Meinck H-M, Thompson P (2002) Stiff man syndrome and related conditions. Mov Disord 17:853–866CrossRefPubMed
67.
Mendell JR, Barohn RJ, Freimer ML et al. (2001) Randomised controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445–449PubMed
68.
Meucci N, Nobile-Orazio E, Scarlato G (1996) Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 243:117–120PubMed
69.
Molina JA, Benito-León J, Bermejo F et al. (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry 60:699–699
70.
Mozuchizuki H, Kamakura K, Masaki T et al. (2002) Motor dominant neuropathy in Sjogren’s syndrome: report of two cases. Intern Med 41:142–146PubMed
71.
Muchnik S, Losavio AS, Vidal A et al. (1997) Long term follow up of Lambert Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 20: 678CrossRef
72.
Noseworthy JH, O’Brien PC, Petterson TM et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514–1522PubMed
73.
Noseworthy JH, O’Brien PC, Weinshenker BG et al. (2000) IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial. Neurology 55:1135–1143PubMed
74.
Nydegger UE, Sturzenegger M (1999) Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21:171–185PubMed
75.
Ogawa T, Taguchi T, Tanaka Y et al. (2001) Intravenous immunoglobulin therapy for diabetic amyotrophy. Intern Med 40:349–352PubMed
76.
Orvieto R, Achiron R, Rotstein Z et al. (1999) Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 82:191–194CrossRefPubMed
77.
Pechadre JC, Sauvezie B, Osier C et al. (1977) The treatment of epileptic encephalopathies with gamma globulin in children. Rev Electroencephalogr Neurophysiol Clin 7:443–447PubMed
78.
Pestronk A, Florence J, Miller T et al. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485–489CrossRefPubMed
79.
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230PubMed
80.
Pradhan S, Gupta RP, Shashank S et al. (1999) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 165:56–61CrossRefPubMed
81.
Qureshi AI, Choudhry MA, Akbar MS et al. (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52:629–632PubMed
82.
Raphael JC, Chevret S, Harboun M et al. (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238CrossRefPubMed
83.
Renaud S, Gregor M, Fuhr P et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611–615CrossRefPubMed
84.
Rewald E, Jaksic JC (1990) Behcet’s syndrome treated with high-dose intravenous IgG and low-dose aspirin. J R Soc Med 83:652–653PubMed
85.
Rich MR, Teener JW, Bird SJ (1997) Treatment of Lambert Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 20:614–615CrossRefPubMed
86.
Richter C, Schnabel A, Csernok E et al. (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2–7PubMed
87.
Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W et al. (1994) Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 24:162–166PubMed
88.
Ronager J, Ravnborg M, Hermansen I et al. (2001) Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 25:967–973CrossRefPubMed
90.
Seider N, Beiran I, Scharf J et al. (2001) Intravenous immunoglobulin therapy for resistant ocular Behcet’s disease. Br J Ophthalmol 85:1287–1288CrossRefPubMed
91.
Sharma KR, Cross J, Ayyar DR et al. (2002) Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 59:751–752CrossRefPubMed
92.
Shillito P, Molenaar P, Vincent A et al. (1995) Acquired neuromyotonia: evidence for autoantibodies directed againstK+ channels of peripheral nerves. Ann Neurol 38:714–722PubMed
93.
Simmons Z, Bromberg MB, Feldman EL et al. (1993) Polyneuropathy associated with IgA monoclonal gammopathy undetermined significance. Muscle Nerve 16:77–83PubMed
94.
Simovic D, Gorson KC, Ropper AH (1998) Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 97:194–200PubMed
95.
Sorensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123–130CrossRefPubMed
96.
Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557–563CrossRefPubMed
97.
Sorensen PS, Wanscher B, Jensen CV et al. (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273–1281PubMed
98.
Stangel M, Boegner F, Klatt CH et al. (2000) A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89–92CrossRefPubMed
99.
Stangel M, Hartung H-P, Marx P et al. (1997) Side effects of high dose intravenous immunoglobulins. Clin Neuropharmacol 20:385–393PubMed
100.
Stangel M, Kiefer R, Pette M et al. (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study. J Neurol 250:818–821CrossRefPubMed
101.
Strasser-Fuchs S, Fazekas F, Deisenhammer F et al. (2000) The Austrian Immunoglobulin in MS (AIMS) Study: final analysis. Mult Scler (Suppl 2) 6:S9–S13
102.
Sugiyama N, Hamano S, Koga M (2003) High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff’s brainstem encephalitis. No To Hattatsu 35:327–330PubMed
103.
Takahashi Y, Takata T, Hoshino M et al. (2003) Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren’s syndrome. Neurology 60:503–505PubMed
104.
Taylor CT, Buring SM, Taylor KH (1999) Treatment of Wegener’s granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 33:1055–1059CrossRefPubMed
105.
Tomer Y, Shoenfeld Y (1992) Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 10:391–393PubMed
106.
Triggs WJ, Young MS, Eskin T et al. (1997) Treatment of idiopathic lumbosacral plexopathy with intravenous immunoglobulin. Muscle Nerve 20:244–246CrossRefPubMed
107.
Van den Berg JS, Van Engelen BG, Boerman RH et al. (1999) Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 246:623–625CrossRefPubMed
108.
Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252PubMed
109.
Van der Meche FGA, Schmitz PIM, Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326:1123–1129PubMed
110.
Van der Meulen MF, Bronner IM, Hoogendijk JE et al. (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321PubMed
111.
Van Doorn PA, Brand A, Strengers PFW et al. (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209–212PubMed
112.
Van Engelen BG, Renier WO, Weemaes CM et al. (1994) Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 19:181–190CrossRefPubMed
113.
Van Koningsveld R, Schmitz PIM, Van der Meché FGA et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363:192–196CrossRefPubMed
114.
Verma A, Bradley WG (1994) High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy. Neurology 44:248–250PubMed
115.
Vermeulen M, Van Doorn PA, Brand A et al. (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39PubMed
116.
Viguier M, Guillevin L, Laroche L (2001) Treatment of parvovirus B19-associated polyarteriitis nodosa with intravenous immune globulin. N Engl J Med 344:1481–1482CrossRef
117.
Villani F, Avanzini G (2002) The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci (Suppl 1) 23:S33-S37
118.
Villani F, Spreafico R, Farina L et al. (2001) Positive response to immunomodulatory therapy in an adult patient with Rasmussen’s encephalitis. Neurology 56:248–250PubMed
119.
120.
Vinjamuri S, Leach JP, Hart IK (2000) Serial perfusion brain tomographic scans detect reversible focal ischaemia in Rasmussen’s encephalitis. Postgrad Med J 76:33–35CrossRefPubMed
121.
Visser LH, Van der Meche FGA, Van Doorn PA et al. (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 118:841–847PubMed
122.
Voltz R (2002) Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis and therapy. Lancet Neurology 1:294–305CrossRefPubMed
123.
Voltz R, Gultekin SH, Rosenfeld MR et al. (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340:1788–1795CrossRefPubMed
124.
Walsh PJ (1991) Treatment of Rasmussen’s syndrome with intravenous gammaglobulin. In: Andermann F (eds) Chronic encephalitis and epilepsy. Rassmussen’s syndrome. Butterworth-Heinemann, Boston, pp 201–204
125.
Walter MC, Lochmüller H, Toepfer M et al. (2000) High-dose immunoglobulin therapiy in sporadic inclusion body myositis: a double-blind, placebo controlled study. J Neurol 247:22–28CrossRefPubMed
126.
Wegner B (2002) Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg 105:3–8CrossRefPubMed
127.
Wise MS, Rutledge SL, Kuzniecky RI (1996) Rasmussen syndrome and long-term response to gamma globulin. Pediatr Neurol 14:149–152CrossRefPubMed
128.
Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: complications and side effects. Eur Neurol 50:172–175CrossRefPubMed
129.
Wolfe GI, Barohn RJ, Foster BM et al. (2002) Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26:549–552CrossRefPubMed
Metadaten
Titel
Einsatz von i. v. Immunglobulinen in der Neurologie
Evidenzbasierter Konsens
verfasst von
Priv.-Doz. Dr. M. Stangel
R. Gold
Publikationsdatum
01.08.2004
Erschienen in
Der Nervenarzt / Ausgabe 8/2004
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-004-1733-4

Weitere Artikel der Ausgabe 8/2004

Der Nervenarzt 8/2004 Zur Ausgabe

Kasuistik

Thrombotisch-thrombozytopenische Purpura

Originalien

Zur Korrelation klinisch-apparativer Differenzialdiagnosen mit neuropathologischen Diagnosen bei Patienten mit Aids

Kasuistik

Rezidivierende zerebrale Ischämien bei zerebraler Vaskulitis im Rahmen eines inkompletten POEMS-Syndroms mit M. Castleman

Originalien

Klinisches Spektrum der Gliedergürtelmuskeldystrophie Typ 2I bei Mutation im „Fukutin-Related-Protein“-Gen

Mitteilungen der DGPPN

Nachwuchsmangel in psychiatrisch-.....

Originalien

Levetiracetam in der Kombinationsbehandlung fokaler Epilepsien

Neu in den Fachgebieten Neurologie und Psychiatrie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Bildnachweise